
STATUTORY INSTRUMENTS

2019 No. 775

The Human Medicines (Amendment
etc.) (EU Exit) Regulations 2019

PART 15

Amendment of Part 14 (advertising)

Amendment of regulation 281 (duties of authorisation holders and registration holders)

213. In regulation 281(1)—

- (a) in sub-paragraph (a), insert “ UK ” before “marketing authorisation”;
- [^{F1}(b) omit “or” at the end of sub-paragraph (c); and
- (c) in sub-paragraph (d), after “for a medicinal product” insert—
“; or
- (e) an EU marketing authorisation for a medicinal product.”.]

Textual Amendments

- F1** Reg. 213(b)(c) substituted (31.12.2020 immediately before IP completion day) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, [Sch. 2 para. 169](#)

Commencement Information

- I1** Reg. 213 in force at 31.12.2020 on IP completion day (in accordance with [2020 c. 1, Sch. 5 para. 1\(1\)](#)), see [reg. 1](#)

Changes to legislation:

There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Section 213.